Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Leukemia. 2013 May 14;27(10):10.1038/leu.2013.151. doi: 10.1038/leu.2013.151

Figure 6. Effect of altered Bcl-xL and BAD expression and activity on BCR-ABL1 signaling in CML-BC.

Figure 6

Schematic representation of the survival/proliferation pathways induced by high levels of BCR/ABL-kinase activity and likely affected by altered Bcl-xL and BAD expression/activity (blue) upon exposure of CML-BC cells to ABT-263 or PP242 (yellow), or after shRNA-mediated downregulation (green) of BAD or hnRNP A1 in CML-BC. Dashed lines indicate pathways normally inactive in CML-BC. Red lines indicate pathways influenced by drug-treatment or shRNA expression.